Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA guanine-7 methyltransferase activating subunit like (RAMACL)
- Target
- RAMACL
- Molecular classification
- Other (predicted pseudogene, paralog of RAMAC; not classified as receptor, enzyme, transporter, etc.)
01
Overview
RAMACL (RNA guanine-7 methyltransferase activating subunit like) is a protein coding gene annotated as a pseudogene and paralog of RAMAC. RAMACL is predicted to enable RNA binding and may be involved (according to sequence homology) in RNA 5'-cap (guanine-N7)-methylation as part of the mRNA capping enzyme complex in the nucleus. However, this function is not experimentally validated for RAMACL, and the canonical function is attributed to its paralog RAMAC, which plays a regulatory role in the mRNA cap methyltransferase complex involved in mRNA metabolism. Therefore, RAMACL itself is not a validated molecular target for therapeutic intervention and is not directly implicated in disease or drug action[1][5].
- Other names
- RNA guanine-N7 methyltransferase-activating subunit-like proteindJ427A4.2C6orf119FAM103A2PRAMMETLRAMMETP1RNMT activating mRNA cap methyltransferase subunit like (pseudogene)RNMT activating mRNA cap methyltransferase subunit pseudogene 1family with sequence similarity 103 member A2, pseudogeneRAMACL
02
Mechanism of action
Not applicable; no drugs target RAMACL
03
Biological functions
No experimentally confirmed functions; predicted to enable RNA binding and possibly participate in mRNA 5'-cap guanine-N7 methylation as a complex subunit, inferred from homology to RAMAC
04
Disease associations
None established; no confirmed role in human disease, but functional RAMAC mutations are associated with Galloway-Mowat syndrome and Seckel syndrome—not RAMACL
05
Safety considerations
None known; there are no safety concerns or therapeutic challenges associated with RAMACL
06
Interacting drugs
None known; no drugs are reported to interact with RAMACL
07
Biomarkers
None known; RAMACL is not established as a biomarker
Beyond the preview
Go deeper on RNA guanine-7 methyltransferase activating subunit like (RAMACL).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA guanine-7 methyltransferase activating subunit like (RAMACL).